OTCMKTS:PMCBD PharmaCyte Biotech (PMCBD) Stock Price, News & Analysis → The Only Energy Play You Should Be Looking At (From Wealthpin Pro) (Ad) Free PMCBD Stock Alerts $2.24 +0.07 (+3.23%) (As of 06/10/2024 ET) Add Compare Share Share Today's Range$2.15▼$2.2850-Day Range$1.96▼$2.5252-Week Range$5.56▼$55.50Volume56,440 shsAverage Volume8,831 shsMarket Capitalization$3.74 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartStock AnalysisChart Get PharmaCyte Biotech alerts: Email Address Ad Wealthpin ProThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy.Click here to get all the information about it. About PharmaCyte Biotech Stock (OTCMKTS:PMCBD)PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Laguna Hills, CA.Read More PMCBD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PMCBD Stock News HeadlinesMarch 19, 2024 | investorplace.comPMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q3 2024February 22, 2024 | investing.comPharmaCyte Biotech Inc (PMCB)October 27, 2023 | ft.comExploring beauty’s biotech frontierMay 26, 2023 | seekingalpha.comPMCB PharmaCyte Biotech, Inc.May 11, 2023 | marketwatch.comPharmaCyte Biotech Shares Up 13% to 52-Week High After Cash Tender OfferApril 28, 2023 | bizjournals.comBaltimore Biotech NewsMarch 30, 2023 | techcrunch.comBiotech & HealthOctober 7, 2022 | finance.yahoo.comPharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder ValueSeptember 28, 2022 | finanznachrichten.deBLACK BIRD BIOTECH INCJuly 28, 2022 | finance.yahoo.comPharmaCyte Biotech Rebukes Iroquois’ Commencement of Consent SolicitationJuly 19, 2022 | apnews.comPharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model StudyJuly 5, 2022 | finance.yahoo.comIROQUOIS CAPITAL ISSUES STATEMENT IN RESPONSE TO RECENT ACTIONS BY THE PHARMACYTE BIOTECH BOARD OF DIRECTORSJune 2, 2022 | seekingalpha.comPharmaCyte Biotech announces $10M share buyback programJune 2, 2022 | seekingalpha.comPharmaCyte Biotech stock rises on $10M stock buyback planJune 2, 2022 | apnews.comPharmaCyte Biotech to Implement $10-Million Share Repurchase ProgramMay 23, 2022 | stockhouse.comPharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant AscitesFebruary 10, 2022 | finance.yahoo.comPharmaCyte Biotech, Inc. (PMCB)January 6, 2022 | finance.yahoo.comPharmaCyte Biotech to Present at H.C. Wainwright BioConnect ConferenceDecember 28, 2021 | businesswire.comPharmaCyte Biotech Successfully Completes 36 Month Master Cell Bank Stability StudyDecember 8, 2021 | stockhouse.comPharmaCyte Biotech Successfully Completes Cytochrome P450 Site of Integration DNA Sequencing AssayNovember 30, 2021 | businesswire.comPharmaCyte Biotech Launches Malignant Ascites Program with Commencement of Pivotal Preclinical StudyNovember 12, 2021 | finance.yahoo.comPharmaCyte Biotech Announces Cell Encapsulation Technology Material Does Not Cause Skin IrritationSeptember 16, 2021 | feeds.benzinga.comWhy Are PharmaCyte Shares Moving Higher On Thursday?August 12, 2021 | finance.yahoo.comPharmaCyte Biotech Announces Closing of $15-Million Public OfferingSee More Headlines Receive PMCBD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PharmaCyte Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolOTCMKTS:PMCBD CUSIPN/A CIKN/A Webwww.pharmacyte.com Phone(917) 595-2850FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,830,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-49.09% Return on Assets-43.39% Debt Debt-to-Equity RatioN/A Current Ratio4.90 Quick Ratio4.90 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares1,671,000Free FloatN/AMarket Cap$3.74 million OptionableNot Optionable Beta0.27 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesKenneth L. WaggonerChairman, President, CEO & SecretaryCarlos A. TrujilloChief Financial Officer & DirectorWalter H. GünzburgsChief Scientific OfficerLinda S. SherChief Medical OfficerJosé L. IglesiasChief Medical OfficerKey CompetitorsTevogen BioNASDAQ:TVGNInhibikase TherapeuticsNYSE:IKTCalidi BiotherapeuticsNYSEAMERICAN:CLDIOrganovoNASDAQ:ONVOCoeptis TherapeuticsNASDAQ:COEPView All Competitors PMCBD Stock Analysis - Frequently Asked Questions How have PMCBD shares performed in 2024? PharmaCyte Biotech's stock was trading at $2.16 at the start of the year. Since then, PMCBD shares have increased by 3.7% and is now trading at $2.24. View the best growth stocks for 2024 here. How do I buy shares of PharmaCyte Biotech? Shares of PMCBD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:PMCBD) was last updated on 6/11/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PharmaCyte Biotech Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share PharmaCyte Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.